Etana Begins Distribution of Locally Produced PCV-13 Vaccine Valenina

PT Etana Biotechnologies Indonesia (Etana) has officially commenced the first distribution phase of its Pneumococcal Conjugate Vaccine (PCV-13) to the Jakarta and Central Java Provincial Health Offices. The vaccine, branded Valenina, is proudly developed and produced locally by Etana.

 The availability of Valenina marks a significant step forward in addressing the need for vaccines that are not only safe and effective but also comply with religious standards. This effort also supports the national agenda of reducing reliance on imported vaccines.

 Through the development of Valenina, Etana reinforces its commitment to providing innovative, high-quality, and accessible healthcare solutions, while playing an active role in the prevention of infectious diseases in Indonesia, particularly pneumonia.